Finance entity
All 1 tracked stories fall under one category: markets. Fermi Inc. is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Source depth averages 4 original sources per story, versus 2.9 across the same-window beat baseline.
Last mentioned: Mar 12, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: markets. Fermi Inc. is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Source depth averages 4 original sources per story, versus 2.9 across the same-window beat baseline. The 5 average consequence score is below the beat benchmark of 6.2 in the same window. Ultragenyx Pharmaceutical Inc. appears in 1 tracked Finance story from March 5, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 98 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Ultragenyx Pharmaceutical Inc.. Shared-story counts are live from our verified record — not editorial picks.
Discovery Phase Begins
Courts likely to rule on motions to dismiss, leading to the exchange of internal corporate documents.
Lead Plaintiff Deadline (Estimated)
Expected window for investors to file motions to lead the class actions against RARE, MREO, and NAVAN.
Coordinated Legal Alerts
Pomerantz Law Firm issues a series of reminders for class action deadlines across four major firms.
Pomerantz Law Firm has issued urgent reminders for investors regarding class action lawsuits against Ultragenyx Pharmaceutical, Fermi Inc., Mereo BioPharma, and Navan, Inc. These legal actions target alleged securities fraud and disclosure failures, setting critical deadlines for lead plaintiff applications.
Ultragenyx Pharmaceutical Inc. is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
